Could an HIV drug tame MS by targeting a common virus?
NCT ID NCT05957913
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether Truvada, an antiviral drug used for HIV prevention, can reduce levels of Epstein-Barr virus (EBV) in people with multiple sclerosis (MS). EBV is linked to MS, and the hope is that lowering the virus might help control the disease. The trial will enroll 50 adults with MS who have evidence of past EBV infection and will monitor virus levels in saliva and blood, along with safety and fatigue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Truvada (tenofovir/emtricitabine)
What this could lead to
If successful, this could point toward a new way to manage multiple sclerosis by targeting the Epstein-Barr virus, potentially reducing disease activity.
What could go wrong
This is a small, early-stage trial focused on virus levels, not on improving MS symptoms directly. The drug is not approved for MS, and side effects or lack of effect on the disease are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States